A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 21, Issue 3, 2010, Pages 903-914

  Quinn, Joseph F ^a,b   Harris, Christopher J ^b   Cobb, Katherine E ^b   Domes, Christopher ^c   Ralle, Martina ^c   Brewer, George ^d   Wadsworth, Teri L ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; amyloid; copper; tetrathiomolybdate; Tg2576

Indexed keywords

AMYLOID BETA PROTEIN; CERULOPLASMIN; COPPER; TETRATHIOMOLYBDIC ACID;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CERULOPLASMIN BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; SPATIAL MEMORY; TRANSGENIC MOUSE;

EID: 77957257626     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100408     Document Type: Article

References (27)

1. Maynard CJ, Cappai R, Volitakis I, Cherny RA, White AR, Beyreuther K, Masters CL, Bush AI, Li QX (2002) Overexpression ofAlzheimer's disease amyloidbeta opposes the agedependent elevations of brain copper and iron. J Biol Chem 277, 4467044676. (Pubitemid 36159056)
2. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J (2004) Copper depletion downregulates expression of the Alzheimer's disease amyloidbeta precursor protein gene. J Biol Chem 279, 2037820386. (Pubitemid 38623484)
3. Kitazawa M, Cheng D, Laferla FM (2009) Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 108, 15501560.
4. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copperzinc chelator markedly and rapidly inhibits betaamyloid accumulation inAlzheimer's disease transgenic mice. Neuron 30, 665676. (Pubitemid 32607332)
5. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, CarringtonD,MavrosC,Volitakis I,XilinasM,AmesD,Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metalprotein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 16851691. (Pubitemid 37521621)
6. Tabira T (2001) Clioquinol's return: Cautions from Japan. Science 292, 22512252.
7. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59, 4355. (Pubitemid 351905863)
8. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as amodifying therapy for Alzheimer's disease: A phase IIa, doubleblind, randomised, placebocontrolled trial. Lancet Neurol 7, 779786.
9. Cater MA, McInnes KT, Li QX, Volitakis I, La Fontaine S, Mercer JF, Bush AI (2008) Intracellular copper deficiency increases amyloidbeta secretion by diverse mechanisms. Biochem J 412, 141152. (Pubitemid 351678344)
10. BayerTA, Schafer S, SimonsA,KemmlingA,KamerT, Tepest R, Eckert A, Schussel K, Eikenberg O, SturchlerPierrat C, AbramowskiD, StaufenbielM, MulthaupG(2003)DietaryCu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A 100, 1418714192. (Pubitemid 37499212)
11. Phinney AL, Drisaldi B, Schmidt SD, Lugowski S, Coronado V, Liang Y, Horne P, Yang J, Sekoulidis J, Coomaraswamy J, Chishti MA, Cox DW, Mathews PM, Nixon RA, Carlson GA, St GeorgeHyslop P, Westaway D (2003) In vivo reduction of amyloidbeta by a mutant copper transporter. Proc Natl Acad Sci U S A 100, 1419314198. (Pubitemid 37499213)
12. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI Cognitive loss in zinc transporter3 knockout mice: A phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci 30, 16311636.
13. Donnelly PS, Caragounis A, Du T, Laughton KM, Volitakis I, Cherny RA, Sharples RA, Hill AF, Li QX, Masters CL, Barnham KJ, White AR (2008) Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloidbeta peptide. J Biol Chem 283, 45684577.
14. Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, NurjonoM, Caragounis A, Du T, Laughton K, Volitakis I, Bush AI, Li QX, Masters CL, Cappai R, Cherny RA, Donnelly PS, White AR, Barnham KJ (2009) Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 106, 381386.
15. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid betapeptide by metaldependent upregulation of metalloprotease activity. J Biol Chem 281, 1767017680. (Pubitemid 44035565)
16. Quinn JF, Crane S, Harris C, Wadsworth TL (2009) Copper in Alzheimer's disease: Too much or too little? Expert Rev Neurother 9, 631637.
17. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J, Fink JK (2003) Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and followup with zinc therapy. Arch Neurol 60, 379385. (Pubitemid 36314363)
18. Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, Hedera P, Moretti P, Fink JK, Tankanow R, Dick RB, Sitterly J (2006) Treatment ofWilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a doubleblind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol 63, 521527.
19. Schosinsky KH LP, Beeler MF (1974) Measurement of Ceruloplasmin from Its Oxidase Activity in Serum by Use of oDianisidine Dihydrocholoride. Clin Chem 20, 15561563.
20. LimGP,Yang F, Chu T,Gahtan E,UbedaO, BeechW,Overmier JB, HsiaoAshec K, Frautschy SA, Cole GM(2001) Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging 22, 983991. (Pubitemid 34066567)
21. ParkerMM,Humoller FL,Mahler DJ (1967) Determination of copper and zinc in biological material. Clin Chem 13, 4048.
22. Brewer GJ (2009) The use of copperlowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs 18, 8997.
23. Hou G, Abrams GD, Dick R, Brewer GJ (2008) Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis. Transl Res 152, 239244.
24. Hou G, Dick R, Zeng C, Brewer GJ (2006) Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models. Transl Res 148, 309314. (Pubitemid 44880042)
25. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, CappaiR, BushAI (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease betaamyloid. FASEB J 18, 14271429. (Pubitemid 39561603)
26. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI (2004) Copper mediates dityrosine crosslinking of Alzheimer's amyloidbeta. Biochemistry 43, 560568. (Pubitemid 38082580)
27. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15, 223240.